Novozymes set up a biopharmaceutical ingredients business to develop and manufacture animal-free recombinant ingredients to support production. The initial focus will be the launch of a range of ingredients developed specifically for industrial-scale mammalian cell culture.
“We are very excited by the launch of this new business and what it represents to the wider biopharmaceutical industry”, says Peter Rosholm, vp for the iIngredients business area. “We have combined Novozymes expertise in large-scale protein production and supply with a strong science base to provide a range of products specifically developed for biopharmaceutical production.
“In addition to addressing the need to produce ever-safer biopharmaceuticals, our cell culture range has a secure supply network to deliver ingredients that allow for process optimization whilst reducing customers regulatory and lot testing burdens.”